Testing two medications after liver cancer surgery to prevent recurrence

Plain-English translation of NCT06454578 on ClinicalTrials.gov ↗ · Source last updated August 2024 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two medications—adebrelimab and apatinib—given after surgical removal of liver cancer. The study focuses on patients whose cancer has a high risk of returning. The goal is to see whether this treatment can help keep the cancer from coming back and improve survival.

Even after successful surgery to remove liver cancer, the disease often returns, especially in patients with aggressive tumors. This medication is designed to boost your immune system to fight any remaining cancer cells and reduce the chance of recurrence.

Do you qualify?

You likely qualify if…

you have been diagnosed with hepatocellular carcinoma (liver cancer) and had surgery to remove it between 4 and 12 weeks before enrollment
you have fully recovered from surgery (within 4 weeks of starting the study)
your cancer had high-risk features such as multiple tumors, large size, poor cell appearance, or signs of vessel invasion
your liver function is reasonably well preserved (Child-Pugh score A or B)
you are in generally good health and able to perform normal activities (ECOG performance status 0-1)
you have not received other systemic anti-cancer treatments for liver cancer before

You likely don't qualify if…

you have received prior chemotherapy, immunotherapy, or other systemic cancer treatment for liver cancer
your blood cell counts or liver function tests are significantly abnormal
you are unable or unwilling to take antiviral treatment if you have hepatitis B or C
you have significant protein in your urine or other major organ function problems
you are pregnant, breastfeeding, or unwilling to use contraception during and after the study

What participation looks like

You would receive the two medications through regular infusions or injections over a treatment period following your surgery. You will have frequent check-ups and blood tests to monitor how well the treatment is working and watch for any side effects. The study involves about 30 patients total, and researchers will evaluate cancer recurrence and survival rates with a mid-term analysis at 6 months after all patients enroll.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Qilu Hospital of Shandong University, Jinan, Shandong

Testing two medications after liver cancer surgery to prevent recurrence

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)

Key details

Contact the research team directly

Interested in joining?